Ascentage Pharma is a clinical-stage biotechnology company focused on developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases. The company's main offerings include a pipeline of drug candidates targeting molecular pathways regulating apoptosis, with a focus on Bcl-...
As an innovative biopharmaceutical company focused on global innovation, Ascentage Pharma has built a high value pipeline composed of assets with first- and best-in-class potentials and conducted more than 40 clinical trials inChina, the US,Australia,Europe, andCanada. In this process, Ascentage...
Ascentage Pharma Group, Inc. 100项与 亞盛醫藥集團 相关的临床结果 Article 作者:Koller, Paul B.;Yang, Dajun;Hunter, Anthony M.;Wang, Cunlin;Uspenskaya, Olga;Shuvaev, Vasily;Fu, Tommy;Jamy, Omer;Wang, Hengbang;Zherebtsova, Vera;Guo, Huanshan;Jiang, Lixin;Cortes, Jorge E.;Lomaia, Elza...
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and ...
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and ...
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-...
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candid...
"We are excited to collaborate with MSD, a pharmaceutical industry leader. APG-115 is a key drug candidate in our development pipeline targeting apoptosis, with great potential in the treatment of advanced solid tumours," said Dr.Dajun Yang, chairman & CEO of Ascentage Pharma. "Based on the ...
The company has built a rich pipeline of innovative drug candidates that includes novel, highly potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways,...
Moreover, Ascentage Pharma has made significant progress with other assets in its pipeline, including APG-1252, a Bcl-2/Bcl-xL dual inhibitor; APG-115, a MDM2-p53 inhibitor; and APG-1387, an IAP antagonist. A number of datasets of those drug candidates were accepted by this year's Americ...